KOSDAQMachinery348340

Neuromeka

₩22,500▲ 7.66%2026-10-02 close

Market Cap

₩522B

Turnover

₩12.7B

Volume

580,000 shares

Shares out.

23.4M

PER

—

PBR

5.8×

EPS

-₩3,334

Dividend Yield

0.00%

PER, EPS, PBR and BPS are calculated in-house from the last 4 quarters (2025Q3–2026Q2) · Dividend yield is based on ₩0 per share · Prices as of the 2026-10-02 close

Report overview

Cobot Leader Neuromeka Recapitalizes Amid Turnaround Push

Neuromeka, the domestic revenue leader in collaborative robots, is expanding growth drivers through automation projects with POSCO and HD Hyundai and a new humanoid business, while simultaneously restructuring its finances through a large rights and bonus share issuance amid continued losses.

1
The company ranked No.1 in the domestic cobot market by 2024 revenue, but 2025 revenue fell to KRW 18.95 billion, down from the prior year.
2
Operating losses have continued through the second quarter of 2026, with net losses sharply widening in the first quarter of 2026 due to a large one-off item.
3
A shareholder rights offering combined with a bonus issue was completed in July–August 2026, with proceeds earmarked for facilities, working capital, and debt repayment.
4
A strategic partnership with POSCO is expanding automation projects from cell-level to line-level scope, and the company unveiled its industrial humanoid platform 'EIR' at CES 2026.
5
Competition from Doosan Robotics, Rainbow Robotics, Universal Robots, and the entry of lower-cost Chinese robots remain ongoing competitive variables.

Business structure

Founded in 2013, Neuromeka is a collaborative robot (cobot) specialist producing the Indy series of cobots, the Moby autonomous mobile robot, the welding-focused OPTi cobot, and the NURI industrial robot platform.

The company unveiled its industrial humanoid platform EIR at CES 2026, expanding its scope toward becoming a comprehensive robotics company. Neuromeka's business structure leans more toward automation-process consulting and systems integration demand than pure robot-unit sales.

Demand for automation-process consulting and systems integration tends to exceed demand for finished robot units, and the company has launched multiple industry- and application-specific robots, with the welding-specialized OPTi cobot as a representative example.

Its key customers include POSCO, HD Hyundai group companies, Curexo, and DN Solutions. It has signed a joint development and supply agreement with Curexo for a medical orthopedic surgical robot, and is pursuing software-based CNC machine-tending automation with DN Solutions.

In December 2024, the company issued a convertible bond and secured a KRW 10 billion investment from POSCO, deepening the strategic relationship, and POSCO Group announced plans to invest KRW 20 trillion by 2030 to automate its production lines, naming Neuromeka a key partner.

With HD Hyundai Samho, the company has applied cobot welding solutions in shipyard settings. Through the HD Hyundai Samho partnership, it absorbed shipyard welding know-how and customer requirements and applied a top-tier cobot welding solution in the field.

Competitively, while Doosan Robotics leans on global distribution and Rainbow Robotics on Samsung Electronics' capital backing, Neuromeka's edge lies in owning both the finished robot and its proprietary actuator, plus a track record with large corporate clients.

Its subsidiary Robolution handles foundry-style contract manufacturing for cobots and industrial robots, and also participates in localizing humanoid actuators.

Earnings trend

Quarterly revenue · Operating profit

₩3.4B-₩4.2B25Q2₩4.5B-₩3.2B25Q3₩7.9B-₩3.5B25Q4₩3B-₩4.3B26Q1₩2.8B-₩5.3B26Q2

RevenueOperating profit

Annual revenue · Operating profit

₩9.8B-₩7.8B2022₩13.7B-₩14.8B2023₩25.3B-₩19B2024₩19B-₩14.9B2025

RevenueOperating profit

Quarterly results · Last 5 quarters
Quarter	Revenue	Operating profit	Op. margin
2025Q2	₩3.4B	-₩4.2B	−121.1%
2025Q3	₩4.5B	-₩3.2B	−70.7%
2025Q4	₩7.9B	-₩3.5B	−44.6%
2026Q1	₩3B	-₩4.3B	−144.2%
2026Q2	₩2.8B	-₩5.3B	−186.6%

Annual results
Year	Revenue	Operating profit	Net income (parent)	Op. margin	ROE	Debt-to-equity
2022	₩9.8B	-₩7.8B	-₩8.2B	−79.9%	−20.6%	10.3%
2023	₩13.7B	-₩14.8B	-₩17.7B	−107.9%	−73.4%	297.9%
2024	₩25.3B	-₩19B	-₩16.7B	−75.2%	−153.4%	776.1%
2025	₩19B	-₩14.9B	-₩22B	−78.4%	−158.3%	557.6%

Consolidated basis (financial statements including subsidiaries) · Final figures from DART filings · Net income attributable to owners of the parent · Data as of 2026-08-21

Earnings analysis

Consolidated revenue rose from KRW 9.75 billion in 2022 to KRW 13.74 billion in 2023 and KRW 25.27 billion in 2024, before declining to KRW 18.95 billion in 2025.

Operating losses remained large relative to revenue throughout the period—KRW 7.8 billion (2022), KRW 14.8 billion (2023), KRW 19.0 billion (2024), and KRW 14.9 billion (2025)—with a 2025 operating margin of -78.4%.

Net loss attributable to owners widened from KRW 8.2 billion in 2022 to KRW 17.7 billion (2023), KRW 16.7 billion (2024), and KRW 22.0 billion (2025), deepening the accumulated deficit.

On a quarterly basis, revenue reached KRW 4.47 billion in Q3 2025 (operating loss KRW 3.16 billion) and KRW 7.87 billion in Q4 2025 (operating loss KRW 3.51 billion), showing year-end revenue seasonality, before dropping again to KRW 2.99 billion in Q1 2026 and KRW 2.82 billion in Q2 2026.

Notably, the Q1 2026 owners' net loss reached KRW 25.62 billion—nearly six times the KRW 4.31 billion operating loss for the same quarter—suggesting a large non-operating item unrelated to the underlying revenue and operating trend.

In Q2 2026, the owners' net loss of KRW 4.50 billion returned to a level closer to the operating loss of KRW 5.27 billion.

The debt ratio climbed sharply from 10.3% in 2022 to 297.9% (2023), 776.1% (2024), and 557.6% (2025), compounding financial strain, while operating cash flow stayed negative for four consecutive years (from -KRW 8.0 billion in 2022 to -KRW 11.4 billion in 2025), underscoring the need for external financing.

Industry analysis

The domestic cobot market is growing on the back of manufacturing labor shortages and expanding automation demand, and Neuromeka ranked No.1 domestically in cobots by 2024 revenue.

However, competitors including Doosan Robotics, Rainbow Robotics, and Universal Robots (Denmark) are numerous, and the entry of low-cost Chinese robots is accelerating, intensifying pricing pressure.

On the demand side, automation needs in heavy industries such as steel, shipbuilding, and batteries are clearly expanding, and in particular POSCO Holdings is reportedly planning roughly KRW 20 trillion in automated production-line investment going forward.

Government-led "physical AI" and humanoid policy support is emerging as a new growth axis; the company was selected for a KRW 17.5 billion "humanoid surgical robot" project in July and a KRW 3.6 billion "high-difficulty AX research support platform" project in September, and was also appointed to the steering committee of the government-organized "K-Humanoid Alliance." Still, many cobot and humanoid companies, Neuromeka included, remain unprofitable, suggesting the industry as a whole is at an early commercialization stage.

Rivals Doosan Robotics and Rainbow Robotics benefit from large-conglomerate backing, giving them a relative funding advantage, while Neuromeka is differentiating through in-house component development and large-corporate partnerships.

Outlook

The company has framed 2026 as a year of business transformation, stating that it planned to launch the world's first cobot-certified humanoid robot, EIR, in the first half of the year, alongside 30kg- and 50kg-class large cobots and a cobot built entirely on domestic technology and components.

Following the CES 2026 unveiling, the company said it would ramp up EIR production to meet automation requests from domestic firms, with sequential production starting in March 2026 and expanding field applications.

The company expects that EIR is pursuing cobot certification, which upon completion would allow deployment in small and mid-sized manufacturing sites without safety fencing.

Regarding the POSCO partnership, it stated that automation scope is expanding from cell-level to line-level, pursuing tens-of-meters-scale line automation spanning four to five connected processes, with plans to eventually scale to factory-wide projects.

Over the longer term, it has been reported that based on the POSCO partnership and regional robotics-ecosystem building, the company set a 2030 revenue target of KRW 600 billion, and to support this, it plans to expand annual production capacity from about 1,200 units to 20,000 units via a new plant in Pohang's Yeongildae industrial complex, targeted for completion in 2027.

Financially, the rights and bonus share issuance completed in July–August 2026 bolstered capital, with proceeds to be deployed sequentially into facilities, working capital, and debt repayment.

These targets, however, are company-stated plans, and the actual pace of conversion into revenue and orders will need further confirmation through upcoming quarterly results.

Valuation

PER

—

PBR

5.8×

ROE

-146.8%

EPS

-₩3,334

BPS

₩2,963

Dividend per share

₩0

Because Neuromeka has posted consecutive losses, conventional earnings-per-share-based valuation metrics are difficult to apply, and the stock has historically traded at a considerable premium relative to net asset value.

Given the large increase in total shares from the 2026 rights and bonus issuance, per-share metrics disclosed going forward should be read with dilution effects in mind. The company has no dividend-payment history since its founding, limiting the relevance of dividend-related metrics.

Price-to-book levels vary widely even within the robotics peer group, reflecting a tendency for market pricing of growth narratives and order expectations to run ahead of reported earnings.

Ultimately, assessing the current valuation level will likely hinge on the pace of revenue recovery and progress in narrowing losses going forward.

PER, EPS, PBR and BPS are all calculated in-house (the same method as Naver and Toss) · Dividend yield = cash dividend per share from DART filings (supplemented by KRX) ÷ current price · As of 2026-08-21

Bull factors

Large-Scale Projects via Big-Corporate Partnerships

The POSCO partnership is expanding from cell-level to line-level scope, and the company has supply and development agreements with a range of large and specialized firms across industries, including HD Hyundai Samho, Curexo, and DN Solutions.

This structure could extend beyond one-off robot sales into recurring maintenance and solutions demand. If POSCO Group's KRW 20 trillion automation investment plan converts into actual orders, it holds potential to become a stable revenue base.

New Business Expansion via Humanoids and In-House Components

The industrial humanoid EIR unveiled at CES 2026 is pursuing cobot certification, which upon completion is expected to allow deployment in small and mid-sized manufacturing sites without safety fencing.

Localization of core components such as actuators and reducers is progressing, offering potential for cost competitiveness and a separate component revenue stream. The contract-manufacturing business of subsidiary Robolution is also growing as an additional revenue source.

Potential Benefit from Government-Led Physical AI and Robotics Policy

The company has successively won government R&D projects and participates in the steering committee of the K-Humanoid Alliance, securing a position within the policy ecosystem.

It has been cited as a potential beneficiary of AI-transformation (AX) policy support, for which trillion-won-scale government funding has been signaled. However, there may be a time lag between policy budget execution and actual revenue contribution.

Bear factors

Revenue Decline and Prolonged Large-Scale Losses

Revenue in 2025 declined to KRW 18.95 billion from KRW 25.27 billion in 2024, and revenue in both Q1 and Q2 2026 came in at only around KRW 3 billion each.

Operating losses remain large relative to revenue scale, and operating cash flow has been negative for four consecutive years, indicating the business cannot yet sustain itself on its own earnings. If the revenue recovery is delayed, the need for additional financing could resurface.

Share Dilution and Financial-Structure Burden

The 2026 rights and bonus share issuance significantly increased total shares outstanding, diluting existing shareholders.

The debt ratio remains elevated at 776.1% in 2024 and 557.6% in 2025, and a sizable portion of the proceeds is earmarked for debt repayment and working capital, potentially limiting room for new investment. If one-off non-operating items recur, as seen in the large Q1 2026 net loss, financial strain could resurface.

Intensifying Competition and Commercialization-Delay Risk

Domestically, well-capitalized rivals such as Doosan Robotics and Rainbow Robotics, and globally, Universal Robots along with an accelerating entry of low-cost Chinese robots, could intensify price competition.

There is no guarantee that the commercialization and mass-production timeline for new products, including the EIR humanoid, will proceed exactly as planned. As the industry overall remains at an early commercialization stage, there is a risk that actual customer adoption could be slower than anticipated.

Risk factors

Financial Risk

Operating cash flow has been negative for four straight years, and the 2025 debt ratio reached 557.6%. While the 2026 rights and bonus issuance temporarily strengthened capital, continued losses could necessitate further external financing.

A significant portion of proceeds is allocated to debt repayment and working capital, potentially limiting actual investment capacity.

Business and Earnings Volatility Risk

Quarterly revenue shows significant variance and tends to concentrate around specific large contracts, limiting earnings predictability.

As seen in Q1 2026, large non-operating losses unrelated to revenue or operating performance can be reflected in the financial statements, making net income volatility larger than the revenue trend would suggest.

Rising revenue dependence on a major client such as POSCO could also increase single-customer concentration risk.

Competitive and Technology Risk

Numerous domestic and international competitors are entering the cobot and humanoid markets, and the spread of low-cost Chinese manufacturers could pressure price competitiveness.

Multiple technology initiatives—actuator and reducer localization, humanoid commercialization—are underway simultaneously, and delays in any of them could dilute the company's technological edge relative to competitors.

What to watch next

Mid-November 2026 (expected)
The Q3 2026 earnings release should be checked for signs of revenue recovery and whether the large non-operating loss seen in Q1 2026 recurs.
During the second half of 2026
Progress on cobot certification for the EIR humanoid, along with any disclosed customer deliveries or proof-of-concept cases, should be monitored.
From Q4 2026 onward
It will be worth watching whether the POSCO automation project expands from line-level to factory-wide scope, and whether additional supply-contract disclosures follow.
2027 (targeted completion of the new Pohang plant)
Progress on the new Pohang plant construction aimed at expanding production capacity, and its actual completion and start-up timing, should be confirmed.
When reviewing the pace of cash burn in upcoming quarters
Given the ongoing scale of losses, it is worth tracking how long the capital raised from the 2026 rights and bonus issuance lasts, and whether discussions of additional financing resurface.

Overall view

Neuromeka holds the No.1 position in domestic cobot revenue and is expanding into humanoids and in-house component manufacturing, backed by partnerships with POSCO and HD Hyundai.

However, 2025 revenue turned negative year-on-year, and losses continued through the first and second quarters of 2026, meaning an earnings turnaround has not yet been confirmed.

The rights and bonus share issuance completed in July–August 2026 strengthened capital, but this also came with dilution for existing shareholders and allocation of proceeds toward debt repayment and working capital.

Multiple growth events are on the horizon—expansion of the POSCO line-level automation project, EIR humanoid certification and commercialization, and construction of the new Pohang plant—making future quarterly results and order disclosures important to monitor.

While the company's technology in-house-development edge relative to peers is clear, the balance between the pace of revenue recovery and the pace of cash burn remains the key variable for future financial stability. This report is for informational purposes only and does not constitute a buy or sell recommendation.

Sources

Korea Exchange (KRX) — Prices · Market Cap · Volume
FSS electronic disclosure system (DART) — Financial statements · Dividend filings

Show 18 more articles and sources

Report written 2026-09-05 · Data as of 2026-09-04

This content is AI analysis of market data and web search results, provided for information only. It is not a solicitation or recommendation to invest. Investment decisions and their consequences are the investor's own responsibility. Data may be delayed or contain errors.